While Alimentation Couche-Tard shareholders have enjoyed solid total returns over five years, a closer look reveals a growing disconnect between its stock performance and underlying profit growth, with recent underperformance adding to investor uncertainty.
Eli Lilly commits $85 million upfront and over $1.8 billion in potential milestones to partner with Repertoire Immune Medicines, aiming to develop a new class of 'tolerizing' therapies that reset the immune system without broad suppression.
The Union Solidarity and Development Party (USDP), backed by Myanmar's military, has secured a commanding majority in the country's protracted general election, a result widely anticipated but condemned by critics as a sham designed to cement junta control.
Eagle Materials Inc. (NYSE:EXP) boasts a Return on Equity nearly double the industry average. But as investors cheer the metric, a deeper look reveals a heavy reliance on debt, raising questions about the sustainability of its impressive performance.
A deep dive into Kadant Inc.'s intrinsic value using a Discounted Cash Flow model suggests the stock is trading near its estimated fair value of $273, raising questions about its near-term upside potential amid current market prices.
Mining giant Rio Tinto and state-owned Aluminum Corporation of China (Chalco) have entered a definitive agreement to acquire a controlling 68.6% stake in Brazil's Companhia Brasileira de Alumínio (CBA) from Votorantim, valuing the deal at approximately $902.6 million. The move signals a major consolidation in the global low-carbon aluminum sector.
Multiple company directors at the UK hydrogen power specialist have invested heavily in its stock over the past year, a move often interpreted as a bullish signal on future prospects, despite the shares trading significantly higher now.
The Institute of Chartered Accountants of Scotland launches its 2026 CA Rising Stars search, introducing a new 'Community and Social Value' award to recognize young professionals driving ethical and technological change in the field.
Valero Energy reported a robust fourth quarter, with net income surging to $1.1 billion, driven by strong refining margins and record operational performance. While renewable diesel faced headwinds, ethanol profits soared. The company outlined disciplined capital plans and highlighted potential tailwinds from policy clarity and increased access to discounted heavy crude.
The Horatio Alger Award bestowed upon ResMed founder Dr. Peter Farrell underscores the company's decades-long leadership in sleep and respiratory care, bringing its financial performance and competitive strategy into sharper focus for investors.
German industrial giant Thyssenkrupp is exploring the sale of a significant minority stake in its Rothe Erde bearings division, a move analysts say could signal a broader portfolio reshuffle and highlight persistent valuation gaps within the conglomerate.
Despite a persistently muted demand environment, Sherwin-Williams reported robust fourth-quarter earnings, driven by cost discipline and strategic acquisitions. The paint giant forecasts low-to-mid single-digit sales growth for 2026 while reinstating employee benefits, signaling cautious optimism amid ongoing economic headwinds.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
As demand for specialist education soars, private investors—from Abu Dhabi to private equity firms—are capitalizing on a strained system, drawing criticism for extracting profits from vulnerable children and cash-strapped councils.
ResMed reports robust revenue and margin expansion in its fiscal Q2 2026, driven by strong device and mask sales. Management highlights strategic investments in AI-powered patient tools and views GLP-1 medications as a potential catalyst for future demand.
Despite facing what its CEO called "highly variable" housing demand in 2025, PulteGroup reported another year of robust revenue and earnings, driven by its diversified buyer mix and strength in the active-adult segment. While Q4 profitability softened, the homebuilder is betting on strategic land investments and a resilient spring selling season to fuel its 2026 outlook.
Parker-Hannifin posts record-breaking Q2 fiscal 2026 results, fueled by robust organic growth and margin expansion, particularly in aerospace. The industrial giant raises full-year guidance and details strategic progress on its planned acquisition of Filtration Group Corporation.
Fractyl Health's Revita procedure shows promise in maintaining weight after stopping GLP-1 drugs, with new six-month data prompting the company to seek a streamlined FDA pathway. A packed 2026 roadmap aims for a U.S. submission, but financial pressures loom.
Meritage Homes concluded a challenging 2025, citing affordability pressures and waning buyer confidence. While maintaining a cautious stance on incentives, the homebuilder is expanding its community footprint and boosting shareholder returns, betting on long-term demographic demand.
Bank of America has upgraded Apellis Pharmaceuticals (APLS) to 'Buy,' citing robust early adoption of its drug Empaveli and significant undervaluation of its potential in treating rare kidney diseases, despite a more cautious outlook from Wells Fargo.
